Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colesevelam meal test study in post-gastric bypass hypoglycemia after cholecystectomy
NL-OMON50934Phase 3Active, not recruiting
- Sponsor
- Medisch Centrum Leeuwarden
- Start
- May 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of colesevelam in post-bariatric hypoglycemia (PBH) (2 arms), sponsored by Medisch Centrum Leeuwarden. Primary endpoint: Glucose nadir during mixed meal test. Started May 2022; status: active, not recruiting.
02
Drugs
colesevelam
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NL-OMON50934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50934.